Skip to Main Content

Author Details

Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
2007
59
26
PMIDPaper TitleJournal TitlePublished Year
37141414Correction: Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migration.Oncotarget2023
36959101Targeting Glutamine Metabolism in Prostate Cancer.Front Biosci (Elite Ed)2023
35115556Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.Nat Commun2022
35562350MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.Nat Commun2022
36636695Activation of ONECUT2 by RB1 loss in castration-resistant prostate cancer.Am J Clin Exp Urol2022
36135315Polycomb Directed Cell Fate Decisions in Development and Cancer.Epigenomes2022
35993978Phenotypic Plasticity - Alternate Transcriptional Programs Driving Treatment Resistant Prostate Cancer.Crit Rev Oncog2022
35175588First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?Drugs2022
34581895Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling.Med Oncol2021
33547292Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nat Commun2021
33899001EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.Nat Cancer2021
33785741Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Nat Commun2021
33863813NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.Mol Cancer Res2021
34552338Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.Onco Targets Ther2021
34466376Use of FVB Myc-CaP cells as an immune competent, androgen receptor positive, mouse model of prostate cancer bone metastasis.J Bone Oncol2021
32461304Targeting RET Kinase in Neuroendocrine Prostate Cancer.Mol Cancer Res2020
32690948Prostate cancer reactivates developmental epigenomic programs during metastatic progression.Nat Genet2020
32917647Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer.Cancer Prev Res (Phila)2020
30655535ONECUT2 is a driver of neuroendocrine prostate cancer.Nat Commun2019
31900914The Role of RB in Prostate Cancer Progression.Adv Exp Med Biol2019
31747605CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.Cell Rep2019
30578319Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.Proc Natl Acad Sci U S A2019
29395951Epigenetic reprogramming: A key mechanism driving therapeutic resistance.Urol Oncol2018
29666280LSD1: A single target to combat lineage plasticity in lethal prostate cancer.Proc Natl Acad Sci U S A2018
28059767Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.Science2017
28401192Evasion of targeted cancer therapy through stem-cell-like reprogramming.Mol Cell Oncol2017
28468521Understanding cancer lineage plasticity: reversing therapeutic resistance in metastatic prostate cancer.Pharmacogenomics2017
29051161Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.Cancer Immunol Res2017
28978058miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth.Oncotarget2017
28925066Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.Prostate2017
28899973TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.Clin Cancer Res2017
28059768SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.Science2017
26973857EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis.Oncoscience2016
27506904HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma.BMC Cancer2016
27225803Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer.Prostate2016
25370534Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.Cancer Immunol Res2015
26658189Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies.Cell Death Dis2015
26578812Advanced neuroendocrine prostate tumors regress to stemness.Proc Natl Acad Sci U S A2015
26720344Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.Cell Death Dis2015
25963421Determination of synthetic lethal interactions to provide therapeutic direction to end aggressive prostate cancer.Future Oncol2015
25960544Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migration.Oncotarget2015
25605014Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.Oncotarget2015
25072314Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.PLoS One2014
25485289Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis.Oncoscience2014
23895657Histone modifications: implications in renal cell carcinoma.Epigenomics2013
24163230Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.Oncotarget2013
21796655Development of a castrate resistant transplant tumor model of prostate cancer.Prostate2012
22917641Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells.Eur J Pharm Sci2012
22303460Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.PLoS One2012
22084164Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.Mol Cancer Ther2012
  • 1 - 50 of 59

Recommended Authors

George V Thomas
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2016
Number of shared co-authors 8
Joshua Urrutia
Knight Cancer Institute, Oregon Health & Science University (OHSU)
Career Start Year 2016
Number of shared co-authors 11
Richard J Rebello
University of Melbourne
Career Start Year 2015
Number of shared co-authors 3
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 17
Alexandra Corella
Fred Hutchinson Cancer Research Center
Career Start Year 2015
Number of shared co-authors 5
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 19
Shuai Gao
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Career Start Year 2012
Number of shared co-authors 23
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 31
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 31
Alastair Davies
University of British Columbia
Career Start Year 2008
Number of shared co-authors 18
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 23
Susana Miranda
The Institute of Cancer Research
Career Start Year 2008
Number of shared co-authors 18
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 44
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 9
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 9
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 29
Adam Sharp
The Institute for Cancer Research
Career Start Year 2003
Number of shared co-authors 23
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 1
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 23
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 8
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 36
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 28
Johann S de Bono
The Institute for Cancer Research
Career Start Year 1999
Number of shared co-authors 38
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 21
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 21
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 33
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 21
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Career Start Year 1995
Number of shared co-authors 36
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 44
Suzanne Carreira
The Institute of Cancer Research
Career Start Year 1990
Number of shared co-authors 16

Collaborators

Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 8
Anjali V Sheahan
Dana-Farber Cancer Institute
Co-authored papers 7
Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers 6
Peter Atadja
Co-authored papers 5
Mark M Pomerantz
Dana-Farber Cancer Institute
Co-authored papers 5
Edwin M Posadas
Cedars-Sinai Medical Center
Co-authored papers 4
Colm Morrissey
Co-authored papers 4
Eva Corey
University of Washington School of Medicine
Co-authored papers 4
Dolores Di Vizio
Cedars-Sinai Medical Center
Co-authored papers 4
Sylvan C Baca
Co-authored papers 4
Ricky W Johnstone
The University of Melbourne
Co-authored papers 4
Stephen J Freedland
Cedars-Sinai Medical Center
Co-authored papers 4
Myles Brown
Co-authored papers 4
Michael R Freeman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 4
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 3
Edward O'Connor
Dana-Farber Cancer Institute
Co-authored papers 3
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 3
Connor Bell
Dana-Farber Cancer Institute
Co-authored papers 3
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 2
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 2
Rosario I Corona
Cedars-Sinai Medical Center
Co-authored papers 2
Amina Zoubeidi
University of British Columbia
Co-authored papers 2
Toni K Choueiri
Dana-Farber Cancer Institute
Co-authored papers 2
Wassim Abida
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Adam G Sowalsky
National Cancer Institute
Co-authored papers 2
Nadia Boufaied
Research Institute of the McGill University Health Centre
Co-authored papers 2
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 2
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 2
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Co-authored papers 2
Release 1.2